Your session is about to expire
← Back to Search
Plasma Volume Expander
Hydroxyethylstarch 130/0.4 for Low Blood Pressure
Phase 4
Waitlist Available
Led By Christian Loubert, MD, FRCPC
Research Sponsored by Maisonneuve-Rosemont Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
The purpose of this trial is to determine the effective volume of hydroxyethylstarch 130/0.4 which would prevent the occurence of maternal hypotension in 50% of healthy pregnant women undergoing a cesarean section under spinal anesthesia.
Eligible Conditions
- Low Blood Pressure
- Fluid Therapy
- Obstetric Anesthesia
- Cesarean Section
- Spinal Anesthesia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2019 Phase 4 trial • 160 Patients • NCT0335021716%
Intraprocedural Bleeding
1%
Delayed Bleed
1%
Abdominal Pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Hetastarch
Eleview
Trial Design
1Treatment groups
Experimental Treatment
Group I: Hydroxyethylstarch 130/0.4Experimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Maisonneuve-Rosemont HospitalLead Sponsor
101 Previous Clinical Trials
38,313 Total Patients Enrolled
Université de MontréalOTHER
219 Previous Clinical Trials
103,112 Total Patients Enrolled
Christian Loubert, MD, FRCPCPrincipal InvestigatorMaisonneuve-Rosemont Hospital
2 Previous Clinical Trials
60 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger